Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Paris November 28, 2019: Bio-Modeling Systems invited to the PolePharma event "Industrie du futur" to present its collaboration with L2F the EPFL AI company adding a third dimension to AI through the Giotto program.
     
  • 2019: PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.
       
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French   therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children in India.
     
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
      
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO of BMSystems, joins Bolero's Pharma/Health Advisory Board to strengthen their services and accelerate the convergence between clinical research and Real Life Data

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
      
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
      
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: www.gemma-project.eu for the World Autism Awareness Day.
     
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that successfully changed the discovery paradigm, addressing the complexity of life sciences mechanisms and the digital "garbage in garbage out" reality through CADI*™ Discovery based on Augmented Intelligence, the other complementary AI, for complex systems.


BMSystems Group addresses two complementary targets in Pharma, Biotech, Cosmetics, Nutrition, BioProduction and digital-Health businesses:

  1. R&D, Translational Medicine, & Digital Health Executives: We offer robust alternative decision-making to de-risk, save time and costs of R&D and Digital Health programs,
  2. Business Developers, Patients Groups & Investors: We discover novel low-risk, highly effective and cost-effective diagnostic, therapy, nutrition, cosmetic, bioprocess solutions for spin-offs or out-licensing.
Created in 2004, profitable since 2006, thanks to our recurrent clients, CADI™ Discovery already delivered operational outputs:
  1. Download BMSystems' CADI Discovey Programs Pipeline
  2. A world's first in CNS diseases with CEA: 2 awards (US & Europe),
  3. Pherecydes-Pharma: First BMSystems' therapeutic spin-off, against MR infections diseases,  Compassionate Use success,
  4. CEA/BMSystems collaborative research success in CNS that led to the co-owned therapeutic class patent with a worldwide exclusive license to a CEA’s spin-off,
  5. 14 R&D validated successes, 8 novel combo-therapies and combo-diagnostics ready for development,,
  6. GEMMA  (Autism & Microbiota) H2020 program with €14.2M funding. BMSystems is the Integrative Biology Partner.  

We warmly invite you to download our Short Corporate Presentation

*Computer Augmented Deductive Intelligence platform.

 

The life-modeling issue: Are we using the right concepts in the righ order?

 

CADI™ : Computer Augmented Deductive Intelligence)